HK1157755A1 - Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) (adp-)(parp) - Google Patents

Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) (adp-)(parp)

Info

Publication number
HK1157755A1
HK1157755A1 HK11111926.3A HK11111926A HK1157755A1 HK 1157755 A1 HK1157755 A1 HK 1157755A1 HK 11111926 A HK11111926 A HK 11111926A HK 1157755 A1 HK1157755 A1 HK 1157755A1
Authority
HK
Hong Kong
Prior art keywords
parp
adp
ribose
polymerase
poly
Prior art date
Application number
HK11111926.3A
Other languages
English (en)
Chinese (zh)
Inventor
Bing Wang
Daniel Chu
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of HK1157755A1 publication Critical patent/HK1157755A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
HK11111926.3A 2008-08-06 2011-11-04 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) (adp-)(parp) HK1157755A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8668708P 2008-08-06 2008-08-06
US15103609P 2009-02-09 2009-02-09
US17308809P 2009-04-27 2009-04-27
PCT/US2009/051879 WO2010017055A2 (fr) 2008-08-06 2009-07-27 Inhibiteurs de poly(adp-ribose)polymérase (parp) de type dihydropyridophtalazinone

Publications (1)

Publication Number Publication Date
HK1157755A1 true HK1157755A1 (en) 2012-07-06

Family

ID=41129519

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11111926.3A HK1157755A1 (en) 2008-08-06 2011-11-04 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) (adp-)(parp)
HK15101138.4A HK1200813A1 (en) 2008-08-06 2015-02-03 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) (adp-)(parp)

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15101138.4A HK1200813A1 (en) 2008-08-06 2015-02-03 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) (adp-)(parp)

Country Status (31)

Country Link
US (7) US8012976B2 (fr)
EP (3) EP3241832A1 (fr)
JP (3) JP5984389B2 (fr)
KR (1) KR101846029B1 (fr)
CN (3) CN103896942A (fr)
AR (1) AR072970A1 (fr)
AU (1) AU2009279944B2 (fr)
BR (1) BRPI0917119B1 (fr)
CA (1) CA2732797C (fr)
CY (3) CY1115022T1 (fr)
DK (2) DK2767537T3 (fr)
ES (2) ES2625817T3 (fr)
FR (1) FR19C1071I2 (fr)
GB (1) GB2462361A (fr)
HK (2) HK1157755A1 (fr)
HR (1) HRP20170982T1 (fr)
HU (2) HUE035295T2 (fr)
IL (1) IL211070A (fr)
LT (2) LT2767537T (fr)
LU (1) LUC00140I2 (fr)
MX (1) MX2011001328A (fr)
NL (1) NL301021I2 (fr)
NO (1) NO2019042I1 (fr)
NZ (1) NZ591166A (fr)
PL (2) PL2326650T3 (fr)
PT (2) PT2326650E (fr)
SG (2) SG193842A1 (fr)
SI (2) SI2767537T1 (fr)
TW (2) TWI448464B (fr)
WO (1) WO2010017055A2 (fr)
ZA (1) ZA201100897B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2767537T1 (sl) 2008-08-06 2017-08-31 Medivation Technologies, Inc. Dihidropiridoftalazinonski inhibitorji poli(adp-riboza) polimeraze (parp)
MX2011006503A (es) 2008-12-19 2011-09-06 Vertex Pharma Derivados de pirazina utiles como inhibidores de la cinasa de atr.
AU2011212928B2 (en) 2010-02-03 2016-06-23 Medivation Technologies Llc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
US20110190266A1 (en) * 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
US8765945B2 (en) * 2010-02-08 2014-07-01 Biomarin Pharmaceutical Inc. Processes of synthesizing dihydropyridophthalazinone derivatives
WO2011130661A1 (fr) * 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Méthodes d'utilisation d'inhibiteurs dihydropyridophthalazinoniques de la poly(adp-ribose) polymérase (parp)
CA2798763A1 (fr) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Composes utiles comme inhibiteurs de la kinase atr
WO2012054698A1 (fr) * 2010-10-21 2012-04-26 Biomarin Pharmaceutical Inc. Sel tosylate de la (8s,9r)-5-fluoro-8-(4-fluorophényl)-9-(1-méthyl-1h- 1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one cristallin
WO2012166151A1 (fr) * 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Utilisation d'inhibiteurs de dihydropyridophtalazinone de poly(adp-ribose) polymérase (parp) dans le traitement d'un syndrome myélodysplasique (mds) et d'une leucémie myéloïde aiguë (aml)
WO2013028495A1 (fr) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Inhibiteurs dihydropyridophthalazinone de poly (adp-ribose) polymérase (parp) pour le traitement du myélome multiple
SG11201401095YA (en) 2011-09-30 2014-04-28 Vertex Pharma Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
EP3878851A1 (fr) 2011-09-30 2021-09-15 Vertex Pharmaceuticals Incorporated Procédé de préparation de composés utiles en tant qu'inhibiteurs de kinase d'atr
CA2860340C (fr) * 2011-12-31 2017-04-25 Beigene, Ltd. Pyridophthalazinones tetra ou pentacycliques fusionnes a utiliser en tant qu'inhibiteurs de parp
US9260440B2 (en) 2011-12-31 2016-02-16 Beigene, Ltd. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors
CA2862706C (fr) 2012-01-20 2021-08-03 Dennis Brown Utilisation d'hexitols substitues, y compris le dianhydrogalactitol et ses analogues, pour le traitement de cellules souches de maladies neoplasiques et de cancers, y compris le g lioblastome multiforme et le medulloblastome
EP2833973B1 (fr) 2012-04-05 2017-09-13 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs d'atr kinase et thérapies combinées les utilisant
WO2014055756A1 (fr) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Procédé pour la mesure d'augmentations de lésions d'adn à médiation par l'inhibition d'atr
WO2014073447A1 (fr) 2012-11-08 2014-05-15 日本化薬株式会社 Composé polymère comprenant un composé camptothécine et un amplificateur de l'effet anti-cancéreux associé à celui-ci, et son utilisation
DK2968316T3 (da) 2013-03-13 2019-10-07 Forma Therapeutics Inc 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-on-derivater og relaterede forbindelser som fedtsyresyntase (fasn)-inhibitorer til behandlingen af cancer
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
WO2015069851A1 (fr) 2013-11-07 2015-05-14 Biomarin Pharmaceutical Inc. Intermédiaires de triazole utiles dans la synthèse de n-alkyltriazolecarbaldéhyde protégés
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
SI3157566T1 (sl) 2014-06-17 2019-08-30 Vertex Pharmaceuticals Incorporated Postopek za zdravljenje raka z uporabo kombinacije inhibitorjev CHK1 in ATR
JP2017523243A (ja) 2014-07-31 2017-08-17 メディヴェイション テクノロジーズ， インコーポレーテッド （２ｓ，３ｓ）−メチル ７−フルオロ−２−（４−フルオロフェニル）−３−（１−メチル−１ｈ−１，２，４−トリアゾール−５−イル）−４−オキソ−１，２，３，４−テトラヒドロキノリン−５−カルボキシレートの共形成剤塩、およびそれらを製造する方法
CA2977685C (fr) 2015-03-02 2024-02-20 Sinai Health System Facteurs de recombinaison homologue
WO2017003723A1 (fr) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Modulateurs de la somatostatine et leurs utilisations
CN107922425B (zh) 2015-08-25 2021-06-01 百济神州有限公司 制备parp抑制剂、结晶形式的方法及其用途
MX2018003657A (es) 2015-09-30 2018-04-30 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr).
US9708319B1 (en) * 2016-06-13 2017-07-18 Yong Xu Synthesis of PARP inhibitor talazoparib
WO2018059437A1 (fr) * 2016-09-27 2018-04-05 Beigene, Ltd. Traitement de cancers à l'aide d'une combinaison comprenant des inhibiteurs de parp
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN108210461A (zh) * 2016-12-16 2018-06-29 中国科学院上海药物研究所 一种Talazoparib药物组合物及其应用
WO2018122168A1 (fr) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinaisons d'inhibiteurs de kinase bub1 et d'inhibiteurs de parp
CN107556312B (zh) * 2016-12-29 2020-04-10 广州丹康医药生物有限公司 具有parp抑制活性的新型稠环化合物、其制备方法和用途
CN107573341B (zh) * 2016-12-29 2020-08-14 广州丹康医药生物有限公司 作为parp抑制剂的新型稠环化合物、其制备方法和应用
WO2018157794A1 (fr) 2017-02-28 2018-09-07 Beigene, Ltd. Formes cristallines de sels de dihydrodiazépinocarazolones téra-cycliques ou penta-cycliques fusionnés, et leurs utilisations
WO2018205938A1 (fr) * 2017-05-08 2018-11-15 广州丹康医药生物有限公司 Inhibiteur de parp, composition pharmaceutique, procédé de préparation et utilisation associés
EP3658560A4 (fr) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. Modulateurs de la somatostatine et utilisations de ces derniers
KR20200071097A (ko) 2017-10-13 2020-06-18 메르크 파텐트 게엠베하 Parp 억제제 및 pd-1 축 결합 길항제의 조합
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN108341792B (zh) * 2018-04-28 2021-09-17 苏州莱克施德药业有限公司 一种Volasertib中间体1-环丙基甲基哌嗪的制备方法
CN108676888B (zh) * 2018-07-12 2022-01-28 吉林大学 一种肺部恶性肿瘤易感性预测试剂盒及系统
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
EP3876940A1 (fr) 2018-11-05 2021-09-15 Pfizer Inc. Combinaisons pour le traitement du cancer
SG11202111402PA (en) 2019-05-14 2021-11-29 Nuvation Bio Inc Anti-cancer nuclear hormone receptor-targeting compounds
ES2966719T3 (es) 2019-05-14 2024-04-23 Suzhou Four Health Pharmaceuticals Co Ltd Derivados de quinazolina-2,4-diona como inhibidores de PARP
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法
WO2021181233A2 (fr) 2020-03-09 2021-09-16 Pfizer Inc. Protéines de fusion et leurs utilisations
US20230414522A1 (en) 2020-11-13 2023-12-28 Pfizer Inc. Talazoparib soft gelatin capsule dosage form
EP4256088A1 (fr) 2020-12-07 2023-10-11 Pfizer Inc. Procédés d'identification d'une tumeur sensible au traitement par le talazoparib et procédés de traitement associés
CA3214408A1 (fr) 2021-03-23 2022-09-29 Nuvation Bio Inc. Composes ciblant des recepteurs hormonaux nucleaires anticancereux
KR20230159510A (ko) 2021-03-24 2023-11-21 화이자 인코포레이티드 Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
AU2022253474A1 (en) * 2021-04-08 2023-11-16 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4089093A1 (fr) * 2021-05-12 2022-11-16 Eberhard Karls Universität Tübingen Medizinische Fakultät Radiosynthèse de [18f] talazoparib
WO2023131894A1 (fr) 2022-01-08 2023-07-13 Pfizer Inc. Perte d'hétérozygotie génomique en tant que biomarqueur prédictif pour le traitement par le talazoparib et méthodes de traitement de cette perte d'hétérozygotie génomique
WO2023201338A1 (fr) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de parp
WO2023233295A1 (fr) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. Dérivés de thiadiazolyle utilisés en tant qu'inhibiteurs d'adn polymérase thêta et leurs utilisations
WO2023239789A1 (fr) * 2022-06-08 2023-12-14 Valo Health, Inc. Inhibiteurs de parp de phtalazinone tricyclique et procédés d'utilisation
CN115572218B (zh) * 2022-08-29 2024-04-16 江阴勒森生物科技有限公司 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法
WO2024074959A1 (fr) 2022-10-02 2024-04-11 Pfizer Inc. Combinaison de talazoparib et d'enzalutamide dans le traitement du cancer de la prostate résistant à la castration métastatique
WO2024127140A1 (fr) 2022-12-17 2024-06-20 Pfizer Inc. Combinaison de talazoparib et d'enzalutamide dans le traitement du cancer de la prostate résistant à la castration et métastatique
CN116283924B (zh) * 2023-01-16 2024-07-26 四川效佳科技有限公司 一种药用级纯度的苯甲酸利扎曲普坦的重结晶方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106631A (en) * 1870-08-23 Improvement in seed-planter
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja) 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
US5328905A (en) * 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
CN1172502A (zh) 1994-08-12 1998-02-04 亿万遗传股份有限公司 17q连锁的乳房癌和卵巢癌易患性基因的体内突变和多态性
DK0705902T3 (da) 1994-08-12 2002-03-11 Univ Utah Res Found 17q-koblet bryst- og ovariecancerprædisponeringsgen
GB9505538D0 (en) * 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
EP1077946A1 (fr) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Composes condenses tricycliques inhibant l'activite de type poly(adp-ribose) polymerase (parp)
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) * 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd 三環性フタラジノン誘導体
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
CA2476406A1 (fr) 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Composes condenses derives de la pyridazine et medicaments contenant lesdits composes comme ingredients actifs
EP1340819A1 (fr) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Marqueurs de microsatellites
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (fr) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase
JPWO2004043959A1 (ja) 2002-11-12 2006-03-09 持田製薬株式会社 新規ｐａｒｐ阻害剤
EP1633724B1 (fr) 2003-03-12 2011-05-04 Kudos Pharmaceuticals Limited Derives de phtalazinone
AU2004242947B2 (en) 2003-05-28 2010-04-29 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP
SG150539A1 (en) 2004-02-18 2009-03-30 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
ES2398606T3 (es) 2007-05-03 2013-03-20 Pfizer Limited Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio
WO2009024190A1 (fr) 2007-08-22 2009-02-26 4Sc Ag Indolopyridines en tant qu'inhibiteurs de la protéine de fuseau kinésine (eg5)
MX2010003564A (es) * 2007-10-03 2010-09-10 Eisai Inc Compuestos inhibidores de poli(adenosina-5'-difosfo-ribosa)polimer asa (parp), composiciones y metodos de uso.
EP2247600A4 (fr) 2008-02-06 2011-09-14 Biomarin Pharm Inc Inhibiteurs à base de composés benzoxazole-carboxamide de l activité poly(adp-ribose)polymérase (parp)
SI2767537T1 (sl) 2008-08-06 2017-08-31 Medivation Technologies, Inc. Dihidropiridoftalazinonski inhibitorji poli(adp-riboza) polimeraze (parp)
BRPI0914556A2 (pt) 2008-08-12 2015-08-04 Boehringer Ingelheim Int Processo para a preparação de compostos de piperazina substituídos por cicloalquila
AU2011212928B2 (en) 2010-02-03 2016-06-23 Medivation Technologies Llc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
US8765945B2 (en) 2010-02-08 2014-07-01 Biomarin Pharmaceutical Inc. Processes of synthesizing dihydropyridophthalazinone derivatives
WO2011130661A1 (fr) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Méthodes d'utilisation d'inhibiteurs dihydropyridophthalazinoniques de la poly(adp-ribose) polymérase (parp)
WO2011140009A1 (fr) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Procédés d'utilisation de glycopeptides semi-synthétiques en tant qu'agents antibactériens
WO2012054698A1 (fr) 2010-10-21 2012-04-26 Biomarin Pharmaceutical Inc. Sel tosylate de la (8s,9r)-5-fluoro-8-(4-fluorophényl)-9-(1-méthyl-1h- 1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one cristallin
WO2012166151A1 (fr) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Utilisation d'inhibiteurs de dihydropyridophtalazinone de poly(adp-ribose) polymérase (parp) dans le traitement d'un syndrome myélodysplasique (mds) et d'une leucémie myéloïde aiguë (aml)
WO2013028495A1 (fr) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Inhibiteurs dihydropyridophthalazinone de poly (adp-ribose) polymérase (parp) pour le traitement du myélome multiple
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
WO2015069851A1 (fr) 2013-11-07 2015-05-14 Biomarin Pharmaceutical Inc. Intermédiaires de triazole utiles dans la synthèse de n-alkyltriazolecarbaldéhyde protégés
JP2017523243A (ja) 2014-07-31 2017-08-17 メディヴェイション テクノロジーズ， インコーポレーテッド （２ｓ，３ｓ）−メチル ７−フルオロ−２−（４−フルオロフェニル）−３−（１−メチル−１ｈ−１，２，４−トリアゾール−５−イル）−４−オキソ−１，２，３，４−テトラヒドロキノリン−５−カルボキシレートの共形成剤塩、およびそれらを製造する方法

Also Published As

Publication number Publication date
PT2767537T (pt) 2017-07-17
CY2019044I1 (el) 2020-05-29
HK1200813A1 (en) 2015-08-14
GB0913474D0 (en) 2009-09-16
US8999987B2 (en) 2015-04-07
CY2019044I2 (el) 2024-02-16
TW201018688A (en) 2010-05-16
NL301021I1 (nl) 2019-12-18
CY1115022T1 (el) 2016-12-14
US8420650B2 (en) 2013-04-16
EP2767537B1 (fr) 2017-04-12
US9820985B2 (en) 2017-11-21
CA2732797A1 (fr) 2010-02-11
CN104478875A (zh) 2015-04-01
NO2019042I1 (no) 2019-11-28
SG10201809895YA (en) 2018-12-28
US20180117045A1 (en) 2018-05-03
US8012976B2 (en) 2011-09-06
NZ591166A (en) 2012-11-30
KR101846029B1 (ko) 2018-04-06
KR20110040973A (ko) 2011-04-20
US10543209B2 (en) 2020-01-28
US20200261454A1 (en) 2020-08-20
US10780088B2 (en) 2020-09-22
TWI448464B (zh) 2014-08-11
SI2767537T1 (sl) 2017-08-31
SG193842A1 (en) 2013-10-30
CY1119218T1 (el) 2018-02-14
HUS1900053I1 (hu) 2020-02-28
PL2767537T3 (pl) 2017-09-29
AU2009279944B2 (en) 2014-09-11
ES2466565T3 (es) 2014-06-10
SI2326650T1 (sl) 2014-04-30
ES2625817T3 (es) 2017-07-20
NL301021I2 (nl) 2020-04-14
CN104478875B (zh) 2017-04-12
EP3241832A1 (fr) 2017-11-08
LTC2767537I2 (lt) 2020-11-10
AU2009279944A1 (en) 2010-02-11
CN102171214A (zh) 2011-08-31
EP2326650A4 (fr) 2012-03-21
LT2767537T (lt) 2017-08-10
IL211070A0 (en) 2011-04-28
JP2011530513A (ja) 2011-12-22
JP2015157843A (ja) 2015-09-03
DK2326650T3 (en) 2014-03-10
CN103896942A (zh) 2014-07-02
LTPA2019522I1 (lt) 2019-12-27
BRPI0917119B1 (pt) 2021-07-13
RU2514937C2 (ru) 2014-05-10
US20150209357A1 (en) 2015-07-30
RU2011108493A (ru) 2012-09-20
EP2326650A2 (fr) 2011-06-01
AR072970A1 (es) 2010-10-06
FR19C1071I1 (fr) 2020-01-17
DK2767537T3 (da) 2017-06-19
FR19C1071I2 (fr) 2020-10-16
US20210069191A1 (en) 2021-03-11
GB2462361A (en) 2010-02-10
HRP20170982T1 (hr) 2017-09-22
PL2326650T3 (pl) 2014-07-31
US11364241B2 (en) 2022-06-21
WO2010017055A2 (fr) 2010-02-11
TW201422617A (zh) 2014-06-16
CA2732797C (fr) 2017-01-03
WO2010017055A3 (fr) 2010-05-27
PT2326650E (pt) 2014-05-06
JP5984389B2 (ja) 2016-09-06
HUE035295T2 (en) 2018-05-02
LUC00140I1 (fr) 2019-12-13
US20110237581A1 (en) 2011-09-29
EP2767537A1 (fr) 2014-08-20
ZA201100897B (en) 2012-06-27
IL211070A (en) 2014-11-30
CN102171214B (zh) 2015-06-24
EP2326650B1 (fr) 2014-02-26
US20100035883A1 (en) 2010-02-11
MX2011001328A (es) 2011-04-04
BRPI0917119A2 (pt) 2015-11-17
US20130190306A1 (en) 2013-07-25
LUC00140I2 (fr) 2021-02-12
EP2326650B9 (fr) 2014-09-10
JP2018012698A (ja) 2018-01-25

Similar Documents

Publication Publication Date Title
HUS1900053I1 (hu) A Poli(ADP-ribóz)-polimeráz (PARP) dihidro-pirido-ftalazinon inhibitorai
HUS1800022I1 (hu) Amid-szubsztituált indazol-származékok mint poli(ADP-ribóz)-polimeráz (PARP) inhibitorok
IL213993A0 (en) Poly (adp-ribose) polymerase (parp) inhibitors
HK1194922A1 (en) Inhibitors of poly(adp-ribose)polymerase (adp-)
EP2247600A4 (fr) Inhibiteurs à base de composés benzoxazole-carboxamide de l activité poly(adp-ribose)polymérase (parp)
IL205142A0 (en) Pyridazinone derivatives as parp inhibitors
ZA200903996B (en) Inhibitors of poly (adp-ribose)polymerase
GB0806915D0 (en) Polymerase inhibitors
GB0806912D0 (en) Polymerase inhibitors
GB0806917D0 (en) Polymerase inhibitors
GB0806914D0 (en) Polymerase inhibitors
GB0806919D0 (en) Polymerase inhibitors
GB0806911D0 (en) Polymerase inhibitors
GB0806920D0 (en) Polymerase inhibitors
GB0806913D0 (en) Polymerase inhibitors